Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session ...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...